We analyzed the distribution of systematic reviews and meta-analyses on cell-expressed CD44 from 1995 to 2022, and the data indicate a research emphasis on gastric and breast cancers, which together accounted for more than 1/3 of all studies (Figure S1). Here, CD44 is linked to breast carcinoma.